Literature DB >> 10896964

Risk of mesothelioma from exposure to crocidolite asbestos: a 1995 update of a South African mortality study.

D Kielkowski1, G Nelson, D Rees.   

Abstract

OBJECTIVE: To find the risk of developing mesothelioma in a cohort born in 1916-36 in Prieska, Northern Cape Province, South Africa.
METHODS: A birth cohort mortality study was carried out in a small town in the Northern Cape Province, South Africa, with a history of crocidolite asbestos mining and milling. The cohort comprised all white births registered in the magisterial district of Prieska from 1916 to 1936, inclusive (2390). Causes of death due to mesothelioma and other cancers as recorded on medical certificates of cause of death were investigated. Person-years analysis was used to calculate mortalities due to mesothelioma, other respiratory cancers, and other non-respiratory cancers. Proportional cancer mortalities were also calculated for mesothelioma and other specific neoplasms.
RESULTS: The follow up rate for the cohort was 74.3% in 1995, and 683 traced members (38.6%) had died. Cause of death was unknown for 6.4% of deaths. There were 118 cases of cancer, 28 of them from mesothelioma, giving a cause specific mortality for mesothelioma of 277 (170-384) per 10(6) person-years. The rates for men and women were 366 and 172 per 10(6) person-years, respectively. The mortality for lung cancer (29 deaths) was 287 (135-436) per 10(6) person-years, and that for other non-respiratory cancers (60 deaths) was 593 (442-745). Two cases of laryngeal and four of colon cancer were observed. All cancer mortality, mesothelioma, and lung cancer proportional cancer mortality ratios were increased.
CONCLUSION: The mortality for mesothelioma in men was twice that in women, probably because men were more likely to have had both occupational and environmental exposure to asbestos. Nevertheless, the mortality in women was still high and is probably indicative of the environmental exposure as white women were rarely employed in the asbestos industry in the Prieska area. Due to the long latency from first exposure to diagnosis of the neoplasm, the cause specific mortality in this cohort could be expected to increase rapidly over the next 10 years.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896964      PMCID: PMC1740004          DOI: 10.1136/oem.57.8.563

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  13 in total

1.  The mortality of amphibole miners in South Africa, 1946-80.

Authors:  G K Sluis-Cremer; F D Liddell; W P Logan; B N Bezuidenhout
Journal:  Br J Ind Med       Date:  1992-08

2.  Mortality of an asbestos-exposed birth cohort. A pilot study.

Authors:  G Reid; D Kielkowski; S D Steyn; K Botha
Journal:  S Afr Med J       Date:  1990-11-17

3.  The discovery of mesothelioma in the northwestern Cape Province in the Republic of South Africa.

Authors:  P E Marchand
Journal:  Am J Ind Med       Date:  1991       Impact factor: 2.214

4.  Case-control study of mesothelioma in South Africa.

Authors:  D Rees; J E Myers; K Goodman; E Fourie; C Blignaut; R Chapman; M O Bachmann
Journal:  Am J Ind Med       Date:  1999-03       Impact factor: 2.214

Review 5.  South African asbestos: production, exports, and destinations, 1959-1993.

Authors:  J S Harington; N D McGlashan
Journal:  Am J Ind Med       Date:  1998-04       Impact factor: 2.214

6.  Non-occupational exposure to asbestos and malignant mesothelioma in females.

Authors:  N J Vianna; A K Polan
Journal:  Lancet       Date:  1978-05-20       Impact factor: 79.321

7.  Mesothelioma incidence and community asbestos exposure.

Authors:  M Berry
Journal:  Environ Res       Date:  1997-10       Impact factor: 6.498

8.  Pleural malignant mesothelioma and environmental asbestos exposure in Casale Monferrato, Piedmont. Preliminary analysis of a case-control study.

Authors:  C Magnani; C Ivaldi; M Botta; B Terracini
Journal:  Med Lav       Date:  1997 Jul-Aug       Impact factor: 1.275

9.  Environmental household exposures to asbestos and occurrence of pleural mesothelioma.

Authors:  D Dodoli; M Del Nevo; C Fiumalbi; T E Iaia; A Cristaudo; P Comba; C Viti; G Battista
Journal:  Am J Ind Med       Date:  1992       Impact factor: 2.214

10.  Mesothelioma in South Africa, 1976-84: incidence and case characteristics.

Authors:  A B Zwi; G Reid; S P Landau; D Kielkowski; P Sitas; M R Becklake
Journal:  Int J Epidemiol       Date:  1989-06       Impact factor: 7.196

View more
  6 in total

Review 1.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

Review 2.  The health impact of nonoccupational exposure to asbestos: what do we know?

Authors:  Marcel Goldberg; Danièle Luce
Journal:  Eur J Cancer Prev       Date:  2009-11       Impact factor: 2.497

Review 3.  New insights into understanding the mechanisms, pathogenesis, and management of malignant mesotheliomas.

Authors:  Brooke T Mossman; Arti Shukla; Nicholas H Heintz; Claire F Verschraegen; Anish Thomas; Raffit Hassan
Journal:  Am J Pathol       Date:  2013-02-08       Impact factor: 4.307

4.  Mesothelioma with non-pleural malignancy: a red herring or just an uncommon pairing?

Authors:  Andrew J Drain; Kourosh Saeb-Parsy; Amit K Shah; D Rassl; Andrew J Ritchie
Journal:  J Cardiothorac Surg       Date:  2006-11-01       Impact factor: 1.637

5.  Asbestos: mining exposure, health effects and policy implications.

Authors:  Kristina Luus
Journal:  Mcgill J Med       Date:  2007-07

6.  Using GIS to Estimate Population at Risk Because of Residence Proximity to Asbestos Processing Facilities in Colombia.

Authors:  Benjamin Lysaniuk; María Fernanda Cely-García; Margarita Giraldo; Joan M Larrahondo; Laura Marcela Serrano-Calderón; Juan Carlos Guerrero-Bernal; Leonardo Briceno-Ayala; Esteban Cruz Rodriguez; Juan Pablo Ramos-Bonilla
Journal:  Int J Environ Res Public Health       Date:  2021-12-17       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.